State Street
PRME icon

State Street’s Prime Medicine PRME Stock Holding History

State Street’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28M Buy
7,576,460
+1,231,335
+19% +$4.09M ﹤0.01% 2192
2026
Q1 		$22.1M Buy
6,345,125
+1,249,615
+25% +$4.76M ﹤0.01% 2196
2025
Q4 		$17.7M Buy
5,095,510
+3,798,884
+293% +$16.9M ﹤0.01% 2337
2025
Q3 		$7.18M Buy
1,296,626
+57,289
+5% +$233K ﹤0.01% 2817
2025
Q2 		$3.06M Buy
1,239,337
+94,032
+8% +$145K ﹤0.01% 3155
2025
Q1 		$2.28M Sell
1,145,305
-8,876
-0.8% -$22.6K ﹤0.01% 3193
2024
Q4 		$3.37M Buy
1,154,181
+7,232
+0.6% +$25.4K ﹤0.01% 3123
2024
Q3 		$4.44M Buy
1,146,949
+43,086
+4% +$200K ﹤0.01% 3020
2024
Q2 		$5.67M Buy
1,103,863
+325,081
+42% +$1.97M ﹤0.01% 2866
2024
Q1 		$5.45M Buy
778,782
+19,024
+3% +$144K ﹤0.01% 2891
2023
Q4 		$6.73M Sell
759,758
-926,243
-55% -$7.14M ﹤0.01% 2792
2023
Q3 		$16.1M Buy
1,686,001
+1,080,802
+179% +$14M ﹤0.01% 2302
2023
Q2 		$8.87M Buy
605,199
+415,771
+219% +$5.8M ﹤0.01% 2706
2023
Q1 		$2.33M Buy
189,428
+74,582
+65% +$1.21M ﹤0.01% 3293
2022
Q4 		$2.13M Buy
+114,846
New +$2.07M ﹤0.01% 3353

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street's PRME Position: Q2 2026 in Review

State Street increased its Prime Medicine (PRME) stake by 19% in Q2 2026, buying an estimated $4.09M and bringing the position to 7,576,460 shares worth $28M. The position accounts for ﹤0.01% of the portfolio, ranked #2192.

State Street first reported a position in PRME in Q4 2022 and has held it in 15 quarters since. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • State Street held 7,576,460 shares of Prime Medicine worth $28M as of Q2 2026.
  • State Street bought 1,231,335 Prime Medicine shares in Q2 2026, an estimated $4.09M.
  • Prime Medicine made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2192 holding.
  • State Street first reported a position in Prime Medicine in Q4 2022 and has held it in 15 quarters since.
  • 188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.